Sera Prognostics Q3 2022: Revenue $87k, Net Loss $10.7M; Banner Health contract signed

SERA PROGNOSTICS, INC.

2022-Q3 EPS reported -$1.11 revenue$203,000

Q3 revenue $87,000, up from $23,000 YoY; net loss $10.7M vs $9.9M.
Operating expenses $11.3M, up from $9.5M; R&D $4.2M, SG&A $7.0M.
Cash, equivalents & securities $111.2M at Sept 30, 2022.
Banner Health signed for PreTRM test under Medicaid plan (~300k members); revenue possible Q4 2022.
PRIME study on track; interim look expected 2023; preeclampsia validation data by year-end 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SERA PROGNOSTICS, INC. reported the third quarter ended September 30, 2022 results: revenue $87,000, net income $10.7 million.

Period: the third quarter ended September 30, 2022
Revenue: $87,000
Net income: $10.7 million
Result: reported results

Exact text from the filing

traction that we believe will create a more significant impact on our top-line results in 2023 and beyond.” Third Quarter 2022 Financial Results Third quarter 2022 revenue of $87,000 compared to $23,000 for the same period of 2021. Total operating expenses were $11.3 million, up from $9.5 million for the third quarter of 2021. Research and development expenses

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

SERA PROGNOSTICS, INC. filing history →

Source: SEC EDGAR

accession 0001534969-22-000129

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.